Diamant Art Company (DIAAF): .0012 UP TODAY

Play Episode

7min

Proactive - Interviews for investors

CleanSpace eyes 30% growth, EBITDA breakeven

CleanSpace Holdings Ltd CEO Gabrielle O’Carroll talked with Proactive about AIM's Small and Midcap Conference about the company’s growth trajectory and product innovation in powered air purifying respirators (PAPRs). CleanSpace was founded in 2009, based on an innovation developed during the SARS epidemic. The company's differentiator is its lightweight, head-mounted respirators that contrast with the bulkier waist-mounted models commonly available in the industrial market. “We are steadily approaching that breakeven EBITDA, profitable EBITDA position, which is our goal,” O’Carroll said. O’Carroll explained that CleanSpace's respirators are well suited for industrial sectors like mining, infrastructure, and petrochemicals. The products are marketed in key regions including the United States, Western Europe, and Australia. The company has 52 employees and recorded AU$9.2 million in revenue in the first half, up 26% year-over-year. CleanSpace is targeting annual revenue growth of 25–30% and expects to achieve positive EBITDA soon. To drive this, the company is focused on raising brand awareness, engaging directly with end users, and supporting occupational hygienists and safety managers. CleanSpace is also investing in R&D to support future product launches. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #CleanSpaceHoldings #IndustrialSafety #RespiratoryProtection #PAPR #WorkplaceSafety #OccupationalHealth #ASXStocks #HealthTech #EBITDA #MiningSafety #InfrastructureSafety #ProactiveInvestors

Proactive - Interviews for investors

Nextech3D.ai unveils AI-powered customer service chatbot, ushering new era of customer engagement

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to introduce the company’s latest innovation: an AI-powered customer service chat agent designed to enhance customer interactions and drive sales. This cutting-edge virtual assistant, integrated directly into Nextech3D.ai’s website, features advanced voice technology from Eleven Labs, enabling natural, human-like conversations. The AI chatbot is engineered to streamline customer support with a range of capabilities, including appointment scheduling, a dynamic knowledge base tailored to Nextech’s services, and seamless transitions to live representatives when needed. By leveraging artificial intelligence, Nextech aims to provide a frictionless, efficient, and engaging experience for its customers. Gappelberg emphasized that the adoption of AI chat agents marks a pivotal step in Nextech3D.ai’s evolution into an AI-first technology company, positioning it to compete at the highest level. The chatbot is not just a tool for customer engagement but also a powerful lead generation asset, automating appointment bookings and capturing high-quality leads to optimize service efficiency. By integrating this AI assistant, Nextech ensures that customers receive accurate, brand-aligned responses to their inquiries while maintaining the option for human support when necessary. With this move, Nextech3D.ai reaffirms its commitment to innovation and sets a new standard for AI-driven customer interactions. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #AmazonSellerCentral #3DModeling #AIPhotography #EcommerceInnovation #3DTechnology #LifestylePhotography #ProactiveInterviews #TechInnovation #AmazonPartners#proactiveinvestors #nextech3d.al

Proactive - Interviews for investors

Digitalbox CEO James Carter on strong 2024 growth and 2025 outlook

Digitalbox PLC (AIM:DBOX) CEO James Carter takes Proactive's Stephen Gunnion through the company’s strong 2024 performance and its strategy heading into 2025. The company delivered a 31% increase in revenue during the year, with Carter describing it as “a good turnaround year.” He pointed to audience growth that outperformed broader news media trends, and revenue growth that exceeded global digital advertising market averages. Carter credited the success to the strength of Digitalbox’s brands and editorial teams, as well as the company’s in-house Graphene Ad Stack technology. “The editorial teams are really very well tuned into what their audiences want,” he said. Among standout performers were TV Guide, which achieved 90% traffic growth in Q4 following a move to a web app format, and The Tab, which benefited from social media asset integration. The Poke also saw a 22% increase in traffic following increased content investment. The company expanded its portfolio from six to eight brands in 2024, aiming to reach ten by the end of 2025. Looking ahead, Carter said 2025 is in line with expectations so far, and Digitalbox remains “cautiously optimistic” amid projected 10% growth in the digital ad market. Visit Proactive’s YouTube channel for more videos, and don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #Digitalbox #JamesCarter #MediaGrowth #DigitalAdvertising #TVGuide #TheTab #OnlineMedia #RevenueGrowth #AdTech #MediaBrands #InvestorUpdate #ProactiveInvestors

Proactive - Interviews for investors

atai CEO outlines strategic focus for 2025 including four major data readouts

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical readouts across atai’s pipeline of short-duration psychedelics, including updates on VLS-01, BPL-003, RL-007 and EMP-01. The company has dosed its first patient in the VLS-01 trial for treatment-resistant depression, a study that includes an innovative two-dose approach. Rao noted, “This will be the first data set that's going to come out that really addresses the question of what is the incremental benefit of a re-dose?” The trial is expected to read out in Q1 of next year. The BPL-003 trial has completed enrolment and is expected to report results mid-year, alongside RL-007, which targets cognitive impairment associated with schizophrenia. EMP-01, which focuses on social anxiety disorder, is also underway with data expected around the same time as VLS-01. Rao also highlighted that atai recently raised additional capital, extending its funding runway into 2027. The company is focused on short-duration psychedelics with easy-to-administer formulations, such as VLS-01's oral strip delivery system. For more interviews and updates from innovative biotech companies, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications for future content. #ataiLifeSciences #Biotech #Pharmaceuticals #PsychedelicTherapy #ClinicalTrials #MentalHealth #TreatmentResistantDepression #Schizophrenia #SocialAnxietyDisorder #VLS01 #RL007 #BPL003 #EMP01 #ProactiveInvestors

Followers	12
Posts	741
Boards Moderated	0
Alias Born	08/01/2012

Volume:	-
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

DIAAF Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free